Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
Abstract Background Aptamer has been called “chemical antibody” which displays the specific affinity to target molecules compared to that of antibodies and possesses several therapeutic advantages over antibodies in terms of size, accessibility to synthesis, and modification. Based on the attractive...
Saved in:
Main Authors: | Do-Hun Kim, Jin-Myung Seo, Kyung-Ju Shin, Su-Geun Yang |
---|---|
Format: | article |
Language: | EN |
Published: |
BMC
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/88acda4cac79433d82657ecc3b6c7ea6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity
by: Dou XQ, et al.
Published: (2018) -
Targeting breast cancer stem cells by a self-assembled, aptamer-conjugated DNA nanotrain with preloading doxorubicin
by: Xu Z, et al.
Published: (2019) -
The Potential Use of Aptamers in The Process of Drug Development
by: Tooba Gholikhani, et al.
Published: (2021) -
Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel
by: Yu Z, et al.
Published: (2020) -
Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy
by: Jurek PM, et al.
Published: (2017)